New drug combo shows promise for untreated lymphoma patients

This study tested a combination of three targeted drugs (mosunetuzumab, polatuzumab vedotin, and obinutuzumab) in 42 people with untreated slow-growing B-cell non-Hodgkin lymphoma. The goal was to see how many patients achieved a complete response (no cancer detected). The drugs work by helping the immune system attack cancer cells or by delivering chemotherapy directly to them. This approach aims to control the disease without the need for lifelong medication, though ongoing monitoring is still required.